Protagonist Therapeutics Announces Presentation of Icotrokinra Phase 2b Trial Results at United European Gastroenterology Week 2025
I'm PortAI, I can summarize articles.
Protagonist Therapeutics, Inc. announced that results from the Phase 2b ANTHEM-UC study of icotrokinra for ulcerative colitis will be presented at the United European Gastroenterology Week 2025 in Berlin on October 7, 2025. The presentation will cover Week 12 results from this randomized, double-blind, placebo-controlled study, focusing on icotrokinra's effects on patients with moderately to severely active ulcerative colitis. Dr. Maria Abreu from Cedars-Sinai Medical Center will deliver the presentation.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments